Evidence map›Paper›PMID 36692829›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2023

Effects of the anti-inflammatory drug celecoxib on cell death signaling in human colon cancer.

Ryuto Maruyama, Yuki Kiyohara, Yasuhiro Kudo, Tomoyasu Sugiyama

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ryuto MaruyamaGraduate School of Bionics, Tokyo University of Technology, 1401-1 Katakura-Machi, Tokyo, Hachioji, 192-0982, Japan. maruyamart@stf.teu.ac.jp.
Yuki KiyoharaGraduate School of Bionics, Tokyo University of Technology, 1401-1 Katakura-Machi, Tokyo, Hachioji, 192-0982, Japan.
Yasuhiro KudoGraduate School of Bionics, Tokyo University of Technology, 1401-1 Katakura-Machi, Tokyo, Hachioji, 192-0982, Japan.
Tomoyasu SugiyamaGraduate School of Bionics, Tokyo University of Technology, 1401-1 Katakura-Machi, Tokyo, Hachioji, 192-0982, Japan.
Tokyo University of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anti-inflammatory drug celecoxib, the only inhibitor of cyclooxygenase-2 (COX-2) with anticancer activity, is used to treat rheumatoid arthritis and can cause endoplasmic reticulum (ER) stress by inhibiting sarco/ER Ca

Indexed as

Colonic NeoplasmsSulfonamidesAnti-Inflammatory AgentsApoptosisCelecoxibCell DeathCyclooxygenase 2 InhibitorsHumansPyrazolesAnti-Inflammatory AgentsCelecoxibCyclooxygenase 2 InhibitorsPyrazolesSulfonamidesCelecoxibEndoplasmic reticulum stressMitochondrial membrane potentialMitochondrial transcription factor ATransmembrane protein 117Uncoupling protein 2

Identifiers

PMID36692829
OpenAlexW4317869772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.